Page of

Share this page

Share this page

Share this page

Share this page

GlaxoSmithKline - SHINGRIX

Prix Galien USA Award Laureates Book

Leave a 'Tweet'

Add your tribute to this Research Team here in words, pictures and video clips.

Dear Colleague As a way of celebrating and sharing The Galien Awards, a page has been created within the $bookTitle$. Here we can all share our memories – through stories, thoughts, messages, photographs and videos. If you would like to visit the page and add your own message simply go to: $findPersonLink$. Thank you,
Previous Page Next

Winning Product 2019 by: Galien Foundation

Date added: 29 Nov 2019

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

In summary, SHINGRIX represents a paradigm shift in the prevention of shingles and a significant step forward in adult immunization overall, delivering never-before-seen levels of vaccine efficacy in the older adult population regardless of age (even in those ≥ 80 years of age). SHINGRIX offers the potential to help protect more people against shingles, and could be a first step towards a new generation of higher-efficacy adult vaccines.

Next Previous